Compare Amylx Pharmaceuticals Inc (AMLX) vs SiTime Corporation (SITM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs SiTime Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while SiTime Corporation trades at $619.93 (market cap $18.83B). The key difference: SiTime Corporation is far larger — about 9.5× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| AMLX | SITM | |
|---|---|---|
Market Cap | $1.98B | $18.83B |
Sector | Health | Technology |
52-Week High | $18.70 | $901.60 |
52-Week Low | $7.64 | $190.16 |
Enterprise Value | $1.70B | $18.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SITM trades at $628.94, down 2.96% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth and consistent earnings beats, with Q1 2026 EPS of $1.44 surpassing estimates. Recent acquisition of Renesas' timing business and raised AI-driven growth guidance highlight strategic expansion. However, negative net income margins and high P/S ratio of 42.42 indicate valuation concerns amid profitability challenges.
Outlook remains positive with 100% analyst buy ratings and a $743.75 consensus target, suggesting 18% upside. Key risks include sustained unprofitability, integration execution from acquisitions, and market volatility. The stock's trajectory hinges on achieving projected 2026 profitability improvements and capitalizing on AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
